Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence

In the EMPA-REG OUTCOME trial, sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, reduced incident or worsening nephropathy. In the LEADER trial, a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, resulted in lower rates of the development and progression of diabetic kidn...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Yamaguchi, Naoki, Adachi, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635773/
https://www.ncbi.nlm.nih.gov/pubmed/36405227
http://dx.doi.org/10.14740/cr1424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635773/
https://www.ncbi.nlm.nih.gov/pubmed/36405227
http://dx.doi.org/10.14740/cr1424

Ejemplares similares